T 1403/24 (Sost antagonist/OSSIFI-MAB) of 08.09.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T140324.20250908
- Date of decision
- 8 September 2025
- Case number
- T 1403/24
- Petition for review of
- -
- Application number
- 18157578.8
- IPC class
- A61K 45/06A61K 38/17A61L 27/12A61K 31/7088A61K 31/713A61K 38/18A61L 27/54A61K 39/395A61P 19/08C07K 16/22A61K 31/59
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- Abstract on Article 099 EPC
- Application title
- METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONIST
- Applicant name
- Ossifi-Mab LLC
- Opponent name
- UCB Pharma GmbH / UCB Pharma S.A.
J A Kemp LLP
Amgen Europe B.V.
Hightone Management Limited - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c)European Patent Convention Art 123(2)European Patent Convention Art 76(1)European Patent Convention Art 99(1)
- Keywords
- Admissibility of opposition - (yes)
Amendments - added subject-matter (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.